Headlines

Pfizer (PFE) said it is optimistic lyme disease vaccine will get registration after 70%-plus efficacy data; says it continues to beat the expectations for revenue or EPS in '24, '25, and Q1 '26

Newsquawk Staff ·

  • China is becoming a "scientific superpower" and its future competition may be Chinese mega players rather than Eli Lilly (LLY) or AstraZeneca (AZN LN) in five years.

Related headlines